PetVivo Holdings, Inc. (PETV) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows mixed signals: strong revenue growth and new partnerships are positive, but high operating losses, cash flow concerns, and reliance on distributors are negative. The Q&A didn't reveal new insights or strong analyst sentiment. Despite record revenue growth, margin pressure and financial health concerns weigh heavily, balancing out the positives. Without clear guidance or market cap data, the overall sentiment is neutral, suggesting a stock price movement within the -2% to 2% range.
Key Financial Performance
Revenue $298,000 for Q1 2026, an increase of 141% year-over-year. This growth was driven by an expanded North American distributor network (192% increase in distributor sales), expanded in-house sales force, and additional product offerings like PrecisePRP.
Gross Profit $187,000 or 63% of revenues, a 69% increase year-over-year. The decrease in gross margin was due to the introduction of the new PrecisePRP product, which altered the sales mix.
Operating Expenses $2 million, a decrease of 9% year-over-year from $2.2 million. This reduction was due to a strategic cost reduction and restructuring program.
Operating Loss $1.8 million, a decrease of 10% year-over-year. This was due to increased sales and reduced operating expenses.
Net Loss $2.3 million or $0.09 per share, a 15% improvement year-over-year from $2 million or $0.11 per share. This improvement was attributed to cost reductions and increased sales.
Net Cash Used in Operating Activities $1.6 million, an increase from $1.5 million year-over-year. This was primarily due to one-time lease termination expenses and increased inventory purchases for the new PrecisePRP product line.
Available Cash $3.3 million as of June 30, 2025, up from $220,000 as of March 31, 2025. The increase was due to $4.7 million in net proceeds from financing activities.
Total Liabilities Decreased by $1.2 million or 39% in the quarter, down to $3.1 million from $5.1 million year-over-year. This reduction included reduced lease liabilities by $860,000 and extinguishment of derivative liabilities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Spryng with OsteoCushion technology: Expanded use across 1,000+ veterinary clinics in all 50 U.S. states and new distribution in Mexico. U.S. distributor sales increased by 192% to $198,000, contributing 67% of total revenue.
PrecisePRP: New platelet-rich plasma product for horses and dogs, launched under exclusive licensing with VetStem. Offers ease of use and consistency, with positive feedback from veterinarians.
Mexico market expansion: Entered the Mexican market, which is expected to grow at an 11% CAGR to $2.4 billion by 2031. Sales in Mexico are ramping up.
U.S. market growth: U.S. animal health market projected to double to $11.3 billion by 2030, providing significant growth opportunities.
Revenue growth: Total revenue increased by 140% to $298,000, driven by distributor sales and new product offerings.
Cost reduction: Operating expenses decreased by 9% to $2 million due to a strategic cost reduction program.
Gross profit: Increased to $187,000, representing 63% of revenues, despite a decrease in gross margin due to new product mix.
AI integration: Collaborating with Digital Landia to integrate pet AI technology with veterinary products, aiming for a commercial launch in Q3 2026.
Equine partnerships: Partnered with Commonwealth Markets to promote Spryng and PrecisePRP in top-tier thoroughbred stables.
Biomaterials R&D: Partnered with PiezoBioMembrane to develop regenerative biomaterials for animals and humans.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Expansion Challenges: While the company has expanded into Mexico and other international markets, there is a risk of underperformance in these new regions due to cultural, regulatory, or logistical challenges.
Revenue Dependency on Distributors: A significant portion of revenue (67%) is derived from distributors, which poses a risk if distributor relationships weaken or fail to meet sales expectations.
High Operating Loss: Despite revenue growth, the company reported an operating loss of $1.8 million, which could impact its financial sustainability if not addressed.
Product Margin Pressure: The introduction of new products like PrecisePRP has led to a decrease in gross margins, which could affect profitability.
Cash Flow Concerns: Net cash used in operating activities increased to $1.6 million, raising concerns about liquidity and operational funding.
Regulatory and Compliance Risks: The company’s uplisting to OTCQX requires adherence to high financial and governance standards, which could pose challenges if not maintained.
Dependence on Strategic Partnerships: The company’s growth strategy heavily relies on partnerships (e.g., VetStem, Commonwealth Markets), which could pose risks if these partnerships falter or fail to deliver expected outcomes.
Supply Chain and Inventory Risks: Increased inventory purchases for new product lines could lead to overstocking or supply chain inefficiencies.
Competitive Pressures: The animal health market is highly competitive, and the company faces risks from established players and new entrants.
Economic and Market Uncertainties: Broader economic conditions and market uncertainties could impact consumer spending on veterinary products and services.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects continued strong sales momentum and market penetration for the duration of fiscal 2026 and beyond, driven by the commercialization of Spryng and PrecisePRP products.
Market Expansion: The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities for the company.
Product Launch: The official commercial launch of the pet AI technology integrated with veterinary products is anticipated in the third quarter of fiscal 2026.
Strategic Partnerships: Collaborations with Commonwealth Markets and PiezoBioMembrane are expected to advance the adoption of Spryng and PrecisePRP in equine health and develop new biomaterials for therapeutic benefits.
Clinical Studies: Completion of the canine elbow pilot study by Orthobiologic Innovations is expected by the end of the calendar year, which will support sales and distribution strategies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the purpose of the safe harbor statement provided by the company?
A:The safe harbor statement is intended to caution regarding forward-looking statements made during the call, which include projections, expectations, and assumptions about the company's future performance. It highlights that these statements are not guarantees and involve risks, uncertainties, and assumptions that could lead to different actual outcomes.
Q:What are the key risks and uncertainties mentioned in the safe harbor statement?
A:The risks and uncertainties include factors detailed in the company's periodic report filings with the SEC, such as the management's discussions and analysis of financial conditions, results of operations, and Risk Factors sections in the annual report on Form 10-K and quarterly reports on Form 10-Q.
Q:Will the company update or revise forward-looking statements made during the call?
A:The company expressly disclaims any obligation to update or revise forward-looking statements to reflect changes in expectations, events, conditions, or circumstances, except as required by law.
Q:Where can the replay of the call be accessed?
A:The replay of the call will be available starting later in the evening or by the next morning. Instructions for accessing the replay are provided in the earnings release and on the company's website at www.petvivo.com.
Q:Review of Unclear Management Responses
A:No questions were directly avoided or lacked clarity, as the session primarily consisted of a safe harbor statement and procedural information without any substantive Q&A.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI technology
Digital Landia
Kansas City
Mexico
OTCQX
OsteoCushion technology
PetVivo veterinarian
PrecisePRP product
Texas
VetStem
addition
advancement
animal human
blood
care
collaboration Commonwealth
equine
force product
future PetVivo
governance
house sale
leuco
liability lease
market animal
material
note
platelet plasma
product offering
solution
stockholder
success
technology PrecisePRP
term
treatment
PETV Transcript
PetVivo Holdings, Inc. (PETV) Q4 2026 Earnings Call Prepared Remarks Transcript
Neutral6-29
PetVivo Holdings, Inc. (PETV) Q3 2026 Earnings Call Transcript
Unknown2-17
The earnings call summary indicates mixed signals: improved balance sheet and strategic cost reductions are positive, but increased operating loss and lack of clear guidance are concerning. The Q&A reveals management's uncertainty about guidance and revenue expectations, which could worry investors. While there are promising developments in product launches and market expansion, the absence of NASDAQ listing plans and unclear future projections temper enthusiasm, leading to a neutral sentiment.
PetVivo Holdings, Inc. (PETV) Q2 2026 Earnings Call Transcript
Positive11-14
The earnings call revealed strong revenue growth and market expansion potential, particularly in the animal health sector. Despite a decrease in gross margins and an increased net loss, the company's strategic initiatives, including partnerships and product launches, are promising. The Q&A highlighted management's transparency about revenue sources and adoption challenges, though specifics were lacking. The strategic partnerships and record revenue growth are positive indicators. Given these factors, the stock price is likely to see a positive movement over the next two weeks.
PetVivo Holdings, Inc. (PETV) Q1 2026 Earnings Call Transcript
Unknown8-14
The earnings call summary shows mixed signals: strong revenue growth and new partnerships are positive, but high operating losses, cash flow concerns, and reliance on distributors are negative. The Q&A didn't reveal new insights or strong analyst sentiment. Despite record revenue growth, margin pressure and financial health concerns weigh heavily, balancing out the positives. Without clear guidance or market cap data, the overall sentiment is neutral, suggesting a stock price movement within the -2% to 2% range.
PETV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
